Related Experiment Video
Updated: Dec 25, 2025
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Recent advances of nanomedicines for liver cancer therapy
Xiaoqin Chi1, Kun Liu2, Xiangjie Luo2
1Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital, Xiamen University, Xiamen 361004, China. xqchi@xmu.edu.cn and The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, The Key Laboratory for Chemical Biology of Fujian Province, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China. hylin007@xmu.edu.cn jhgao@xmu.edu.cn.
Abstract:
Liver cancer is one of the most prevalent cancers and the third leading cause of cancer-related deaths worldwide. Liver cancer is insensitive to chemotherapeutic drugs due to its intrinsic or acquired drug resistance and the inability of delivering sufficient drugs to tumors via current chemotherapy. The emergence of nanomedicines offers a potential solution for this challenge. Nanomedicines utilize nanoscale or nanostructured materials in medicines for particular medical purposes. In this review, we illustrate the recent developments of various nanomedicines for liver cancer by presenting selected examples at different stages. Diverse nanomaterials, varied targeting moieties, and specific strategies for controlled release of nanomedicines for liver cancer therapy are summarized. Multifunctional nanomedicines for liver cancer are also discussed. This comprehensive review is aimed at providing quick access for readers to the cutting-edge nanomedicines in liver cancer therapy.
Insights
Nanomedicines offer a promising approach to overcome drug resistance in liver cancer therapy. This review highlights recent advancements in nanomedicine for treating liver cancer, focusing on diverse nanomaterials and targeted delivery strategies.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Liver cancer is a leading cause of cancer mortality globally.
- Conventional chemotherapy faces challenges due to drug resistance and poor drug delivery in liver cancer.
- Nanomedicines present a novel strategy to address these limitations.
Purpose of the Study:
- To review recent developments in nanomedicines for liver cancer therapy.
- To summarize diverse nanomaterials, targeting moieties, and controlled-release strategies.
- To discuss multifunctional nanomedicines for enhanced liver cancer treatment.
Main Methods:
- Literature review of nanomedicine applications in liver cancer.
- Analysis of selected examples across different developmental stages.
- Synthesis of information on nanomaterial diversity, targeting, and release mechanisms.
Main Results:
- Diverse nanomaterials are being explored for liver cancer treatment.
- Targeting moieties enhance drug specificity and efficacy.
- Controlled-release strategies improve therapeutic outcomes.
- Multifunctional nanomedicines show potential for combination therapies.
Conclusions:
- Nanomedicines represent a significant advancement in liver cancer treatment.
- Targeted delivery and controlled release are key features of effective nanotherapeutics.
- Further research into multifunctional nanomedicines holds promise for improved patient outcomes.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...